Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hyloris Pharmaceuticals's Other Operating Expense for the
six
months ended in Dec. 2025 was €-0.86 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.63 Mil.
Hyloris Pharmaceuticals's quarterly Other Operating Expense
increased
from Dec. 2024 (€-0.80 Mil) to Jun. 2025 (€-0.76 Mil) but then
declined
from Jun. 2025 (€-0.76 Mil) to Dec. 2025 (€-0.86 Mil).
Hyloris Pharmaceuticals's annual Other Operating Expense
increased
from Dec. 2023 (€-2.13 Mil) to Dec. 2024 (€-1.29 Mil) but then
declined
from Dec. 2024 (€-1.29 Mil) to Dec. 2025 (€-1.63 Mil).
Hyloris Pharmaceuticals Other Operating Expense Related Terms
Hyloris Pharmaceuticals Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Hyloris Pharmaceuticals's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hyloris Pharmaceuticals Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of €-1.63 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Other Operating Expense of €-1.63 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Other Operating Expense too high?
Hyloris Pharmaceuticals' current Other Operating Expense is €-1.63 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Other Operating Expense compare to VRTX and REGN?
Hyloris Pharmaceuticals' Other Operating Expense of €-1.63 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Other Operating Expense is €-1.63 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Hyloris Pharmaceuticals (LTS:0AB6) has a current Other Operating Expense of €-1.63 Mil. The stock's GF Value™ is €9.65, compared to a current price of €4.70 — trading 51.3% below its estimated fair value. The current Other Operating Expense is €-1.63 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Other Operating Expense is €-1.63 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.70 is trading 51.3% below its estimated GF Value™ of €9.65.
Key valuation signals for LTS:0AB6:
Other Operating Expense: €-1.63 Mil
GF Value™: €9.65 vs. price of €4.70 (51.3% below fair value)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
64GF Score
Get the complete analysis for LTS:0AB6
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
